BLACKSTONE LIFE SCIENCES
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.
BLACKSTONE LIFE SCIENCES
Status:
Active
Similar Organizations
BBH Capital Partners
The private-equity arm of New York
Oaktree Capital Management
Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Platform Ventures
Platform Ventures, a real estate private equity investment firm.
Rhone Capital
Rhone Capital is a private equity arm of Rhone Group.
Current Advisors List
Advisor
2018-12-01
Advisor
2009-01-01
Current Employees Featured
Stephen Schwarzman Founder @ Blackstone Life Sciences
Founder
Evan Rachlin Principal @ Blackstone Life Sciences
Principal
2019-01-01
Nicholas J. Simon Senior Managing Director @ Blackstone Life Sciences
Senior Managing Director
2018-12-01
Kurt Wheeler Senior Managing Director @ Blackstone Life Sciences
Senior Managing Director
2018-12-01
Emmett Cunningham Senior Managing Director @ Blackstone Life Sciences
Senior Managing Director
2018-12-01
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-15 | Sanofi | Blackstone Life Sciences investment in Post-IPO Equity - Sanofi | 300 M EUR |
| 2021-08-10 | Harmony Biosciences | Blackstone Life Sciences investment in Post-IPO Equity - Harmony Biosciences | 30 M USD |
| 2020-11-19 | Imago BioSciences | Blackstone Life Sciences investment in Series C - Imago BioSciences | 80 M USD |
| 2020-10-06 | Talaris Therapeutics | Blackstone Life Sciences investment in Series B - Talaris Therapeutics | 115 M USD |
| 2020-07-28 | Praxis Precision Medicines | Blackstone Life Sciences investment in Series C - Praxis Precision Medicines | 110 M USD |
| 2020-07-01 | Annexon Biosciences | Blackstone Life Sciences investment in Series C - Annexon Biosciences | 100 M USD |
| 2020-06-15 | Medtronic | Blackstone Life Sciences investment in Post-IPO Equity - Medtronic | 337 M USD |
| 2020-06-11 | Reata Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Reata Pharmaceuticals | 350 M USD |
| 2020-04-13 | Alnylam Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Alnylam Pharmaceuticals | 250 M USD |
More informations about "Blackstone Life Sciences"
Blackstone Life Sciences and Anthos Therapeutics Announce …
CAMBRIDGE, Mass., February 11, 2025 – Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company …See details»
Blackstone Life Sciences - Crunchbase
Blackstone Life Sciences (BXLS) operates in the biotechnology sector, focusing on investments in advanced healthcare technologies to improve patient outcomes. The firm invests in both early and late-stage biotechnology and …See details»
Anthos Therapeutics Appoints Will Kane as President and Chief ...
Oct 31, 2024 Anthos Therapeutics was founded by Blackstone Life Sciences in 2019 and obtained from Novartis Pharma AG the exclusive global rights to develop, manufacture, and …See details»
How Blackstone Bolted Past Rivals in Life Sciences
May 13, 2024 Blackstone’s business model is well suited for life sciences. Its $1 trillion of assets under management are spread over more than 230 portfolio …See details»
Blackstone Life Sciences and Novartis Launch Anthos Therapeutics …
Feb 27, 2019 Blackstone Life Sciences is a private investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors. By …See details»
Blackstone Life Sciences and Anthos Therapeutics Announce
Feb 11, 2025 Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science …See details»
Blackstone Life Sciences investment portfolio - PitchBook
Oct 18, 2024 Blackstone Life Sciences's latest investment was on 18-Oct-2024 in AvenCell, a company within the Biotechnology industry. Data Transparency. Meet our data hygiene team. …See details»
Blackstone targets $5 billion for latest life sciences fund
Dec 9, 2024 Blackstone is back on the fundraising trail for its latest life sciences fund, targeting $5 billion in investor commitments, the Wall Street Journal reported, citing pension documents.. The fundraising efforts come roughly four …See details»
John Maraganore, Ph.D. - ARCH Venture Partners
He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, and Senior Advisor for Blackstone Life Sciences. He is also a member of the Board of Directors of …See details»
Blackstone Launches New $5B+ Fund for Life Sciences
Jan 31, 2025 The same month, Bain Capital Life Sciences matched ARCH’s raise with a $3 billion fund of its own, earmarked for biopharma players working on “transformative medicines, medical devices, diagnostics, and life sciences …See details»
Blackstone Life Sciences, Cellex Cell Professionals, and ... - AvenCell
Jun 22, 2021 Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science …See details»
Blackstone Buys Japan Drug Trial Firm, Adding to PE Health Deals
Mar 3, 2025 Blackstone has invested in several drugs in late clinical testing through its Life Sciences fund, and its ownership of CMIC could help bring the treatments to market in Japan …See details»
Blackstone Life Sciences Launches Uniquity Bio to Develop Novel ...
NEW YORK, May 15, 2024--Blackstone (NYSE:BX) today announced the launch of the Blackstone Life Sciences ("Blackstone") portfolio company Uniquity Bio, a clinical-stage drug …See details»
Kurt Wheeler - Senior Managing Director @ Blackstone Life …
Kurt Wheeler is the Senior Managing Director at Blackstone Life Sciences. He attended Northwestern University - Kellogg School of Management. ... Edit Partner Investments …See details»
Blackstone Life Sciences and Anthos Therapeutics Announce …
Feb 11, 2025 Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science …See details»
Private Equity Report: 2024 Trends & 2025 Outlook
Feb 12, 2025 Healthcare & Life Sciences Manufacturing & Consumer Goods Private Client Services Private Equity Professional Services ... Blackstone’s $16 billion acquisition of …See details»
Blackstone Unveils Immunology Startup With $300M and a Phase …
May 15, 2024 Blackstone Life Sciences invests in companies at various stages of development. In March, the firm announced it would provide up to $750 million to fund Moderna’s messenger …See details»
Blackstone Life Sciences to invest up to $250 million in
Nov 8, 2021 Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science …See details»
TRSL backs Blackstone funds | Private Equity International
Dec 17, 2024 Blackstone Life Sciences VI is a growth equity fund that focuses on investments in the biotech/life sciences sector in North American. The fund has a target size of $5 billion. Its …See details»
Medtronic inks up to $337M in diabetes funding, Blackstone Life ...
Jun 15, 2020 Dive Brief: Medtronic announced Friday that Blackstone Life Sciences has agreed to provide up to $337 million in funding to its diabetes portfolio, marking the segment of the …See details»